Radiofrequency ablation eliminates nondysplastic BE

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 9
Volume 17
Issue 9

Radiofrequency ablation (RA) is effective for the complete eradication of nondysplastic Barrett’s esophagus (BE), according to researchers from the Academic Medical Center in Amsterdam.

ABSTRACT: Studies finds RA, with or without prior endoscopic resection, proves safe for removal of Barrett’s esophagus and associated neoplasia.

Radiofrequency ablation (RA) is effective for the complete eradication of nondysplastic Barrett’s esophagus (BE), according to researchers from the Academic Medical Center in Amsterdam.

 

Roos E. Pouw, MD, and colleagues enrolled 44 patients who had BE (median of 7 cm) with early neoplasia. Visible lesions were endoscopically resected. Circumferential and focal ablation was repeated every 2 months until the entire Barrett epithelium was eradicated (Journal of Gastrointestinal Surgery online, August 13, 2008).

 

Among 31 patients, 16 first underwent endoscopic resection for early cancer, 12 had high-grade dysplasia, and 3 displayed low-grade dysplasia. After resection, the worst remaining histology was high-grade in 32 cases, low-grade in 10 cases, and 2 without dysplasia.

 

Post-ablation, complete histological eradication of all dysplasia and intestinal metaplasia was achieved in 43 patients.

Related Videos
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
A panel of 4 experts on multiple myeloma
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Video 1 - 4 KOLs are featured in "Triaging and Prioritizing Patients with Multiple Myeloma"
Video 1 - 4 KOLs are featured in "CAR T-Cell Therapy: Leukapheresis Practices"
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Overall survival data with blinatumomab in the phase 3 E1910 study may be an “important development” in CD19-positive B-ALL.
Related Content